Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA)

FDA to Tighten Oversight of Supplements

MONDAY, Feb. 11, 2019 — The U.S. Food and Drug Administration plans to strengthen regulation of dietary supplements, such as vitamins, minerals and herbs, the agency announced Monday. The changes would be “one of the